Abstract
Background and aims
A 5-bp insertion–deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested.
Methods
Genotype was determined by 4% polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn’s disease, 20 ulcerative colitis) PBL samples.
Results
The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD.
Conclusions
These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.
Similar content being viewed by others
References
Reik W (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447:425–432
Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597–610
Kerkel K, Spadola A, Yuan E et al (2008) Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 40:904–908
Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117
Moser D, Ekawardhani S, Kumsta R et al (2009) Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology 34:458–467
Wang H, Ogawa M, Wood JR et al (2008) Genetic and epigenetic mechanisms combine to control MMP1 expression and its association with preterm premature rupture of membranes. Hum Mol Genet 17:1087–1096
Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517
Sathiyasekaran M, Shivbalan S (2006) Crohn's disease. Indian J Pediatr 73:723–729
Petronis A (2006) Epigenetics and twins: three variations on the theme. Trends Genet 22:347–350
Biank V, Broeckel U, Kugathasan S (2007) Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis 13:1430–1438
Petronis A, Petroniene R (2000) Epigenetics of inflammatory bowel disease. Gut 47:302–306
Tahara T, Shibata T, Nakamura M et al (2009) Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int J Mol Med 23:521–527
Tahara T, Shibata T, Nakamura M et al (2009) Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med 9:125–130
Dideberg V, Kristjansdottir G, Milani L et al (2007) An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 16:3008–3016
Sigurdsson S, Goring HH, Kristjansdottir G et al (2008) Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17:872–881
Brandeis M, Frank D, Keshet I et al (1994) Sp1 elements protect a CpG island from de novo methylation. Nature 371:435–438
Magyari L, Farago B, Bene J et al (2007) No association of the cytotoxic T-lymphocyte associated gene CTLA4 +49A/G polymorphisms with Crohn's disease and ulcerative colitis in Hungarian population samples. World J Gastroenterol 13:2205–2208
Waterland RA, Jirtle RL (2003) Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23:5293–5300
Shen L, Guo Y, Chen X, Ahmed S, Issa JP (2007) Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 42:48–52
Colella S, Shen L, Baggerly KA, Issa JP, Krahe R (2003) Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146–150
Bock C, Walter J, Paulsen M, Lengauer T (2008) Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping. Nucleic Acids Res 36:e55
Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagnostics 9:368–381
Gazzoli I, Kolodner RD (2003) Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms. Mol Cell Biol 23:7992–8007
Acknowledgments
R.K. was supported by funding from the Broad Medical Research Program, the Broad Foundation (IBD-0252), and a young investigator joint award from the Crohn’s and Colitis Foundation of America—Children’s Digestive Health and Nutrition Foundation/North American Society of Pediatric Gastroenterology Hepatology and Nutrition (CCFA Ref #2426).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balasa, A., Gathungu, G., Kisfali, P. et al. Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases. Int J Colorectal Dis 25, 553–556 (2010). https://doi.org/10.1007/s00384-010-0874-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-010-0874-0